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Accepted 19 May 2016Physiologic changes in awoman’s life, such as childbirth,weightﬂuctuations, and hormonal changes due to
aging and menopause, may alter the laxity of the vaginal canal, damage the pelvic ﬂoor, and devitalize the
mucosal tone of the vaginal wall. These events often lead to the development of genitourinary conditions
such as stress urinary incontinence; vaginal atrophy; dryness; and physiologic distress affecting a woman’s
quality of life, self-conﬁdence, and sexuality. Various treatment modalities are currently available to
manage these indications, varying from invasive vaginal surgery to more benign treatments like topical
vaginal hormonal gels or hormone-replacement therapy. A new trend gaining momentum is the advent
of energy-based devices for vaginal rejuvenation that apply thermal or nonthermal energy to the various
layers of the vaginal tissue, stimulating collagen regeneration contracture of elastin ﬁbers, neovasculariza-
tion, and improved vaginal lubrication. This review aims to present the available technologies offering
vaginal rejuvenation and the scientiﬁc evidence that underlines their safety and efﬁcacy for this indication.
© 2016 The Authors. Published by Elsevier Inc. on behalf of Women's Dermatologic Society. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Patient conﬁdence and enthusiasm over the safety and documented
efﬁcacy of minimally invasive aesthetic procedures has spawned into
seeking new indications and anatomical concerns to conquer. The
aesthetics of the female genitalia have become an area of particular
concern among women over the past decade, reinforced by the
popularity of Brazilian waxing, fashion trends, and media promotion
of nude images. Women in increasing numbers are choosing to alter
their genital anatomy to gain greater self-esteem, diminish functional
discomforts and difﬁculties, and improve sexual pleasure. Due to
various causes ranging from childbirth and aging to genetics or even
trauma, the female genital region becomes loose and lax over time,
resulting in stress urinary incontinence, atrophic vaginitis, decreased
sensation during coitus, and generalized dissatisfaction with the
appearance of the area (Grifﬁths et al., 2006; Pauls et al., 2008a,
2008b, 2012). Thus, for both cosmetic and medical reasons, women
seek to revitalize and strengthen the elasticity of the vaginal wall
and hydration of the vaginal mucosa.
Vaginal rejuvenation, a marketing rather medical nomenclature, is
an umbrella term used to describe a range of aesthetic and functional. Sadick).
Inc. on behalf of Women's Derprocedures that correct and restore the optimal structure of the vagina
and surrounding tissues. On the one end of the spectrum lie noninva-
sive strategies that serve as a ﬁrst-line approach to improving vaginal
atrophy and dryness, such as lubricants and hormone replacement
medications or rather ineffective Kegel exercises aiming to strengthen
the pelvic ﬂoor muscles. On the other end, gynecologic or plastic
surgeons perform invasive procedures such as labiaplasty to alter the
labia minora and majora and the folds of skin surrounding the
human vulva or vaginoplasty, which involves surgery to the pelvic
ﬂoor (Benadiba, 2010; Dobbeleir et al., 2011; Goodman et al., 2016;
Gowda et al., 2015; Grifﬁths et al., 2006;Hamori, 2014; Kent and Pelosi,
2012; Pauls et al., 2008a, 2008b, 2012).
Recently, however, surgical procedures and systemic and topical
treatments have been supplemented with new, noninvasive, energy-
based systems, which is a welcome development for the many
women wary of surgery due to the risk, expense, and downtime in-
volved. These devices have opened up a new market for nonsurgical
vulvovaginal correction procedures that can be performed by a wider
range of practitioners including dermatologists.
Among the newmodalities being applied to feminine rejuvenation
include CO2-based or erbium:yttrium-aluminum-garnet (Er:YAG)
lasers and radiofrequency (RF)-based energy devices (Table 1). By
harnessing laser or RF waves to heat the connective tissue of the
vaginalwall to 40 °C to 42 °C, these energy-based devices aim to inducematologic Society. This is an open access article under the CC BY-NC-ND license
Table 1
Laser and Radiofrequency-Based Devices for Vaginal Rejuvenation.
Laser-based devices Number of treatments
FemiLift Alma Lasers (Buffalo Grove, IL) Fractional CO2 laser 3 Tx at 4–6 wk intervals
MonaLisa Touch, Cynosure (Westford, MA) Fractional CO2 laser 3 Tx at 6 wk intervals
IntimaLase, Fotona (Dallax, TX) 2,940-nm nonablative Er:YAG 2 Tx at 8 wk intervals
Petit Lady, Lutronic (Burlington, MA) 2,940-nm Er:YAG 3 Tx at 2 wk intervals
Radiofrequency-based devices
ThermiVa, ThermiAesthetics (Southlake,TX) Temperature-controlled radiofrequency 3 Tx at 4–6 wk intervals
ReVive, Viora (Jersey City, NJ) Bipolar radiofrequency 4-6 Tx at 2–3 wk intervals
Venus Fiore, VenusConcept (Toronto, CA) Multipolar-radiofrequency with pulsed electromagnetic ﬁeld 3 Tx at 1 wk intervals
Viveve System, Viveve Medical (Sunnyvale, CA) Patented radiofrequency 1 Tx
Protégé Intima, BTL Aesthetics, (Framingham, MA) Focused radiofrequency 2-4 Tx every 2–3 wks
Pelleve, Ellman International (Hicksville, NY) Monopolar radiofrequency 3 Tx at 2–3 wk intervals
Tx = Treatment.
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factor inﬁltration that ultimately revitalize and restore the elasticity
and moisture of the vaginal mucosa. Although numerous studies
have demonstrated the therapeutic efﬁcacy of energy-based devices
in rejuvenation of the face, neck, and decollete, their application in
the vaginal canal is a fairly new concept with a paucity of clinical
studies currently available to validate their efﬁcacy. Nevertheless, a
plethora of devices are currently available, marketed, and developed
with speciﬁc hand-pieces for this indication. The array of these devices,
their underlying mechanism of action, and any available studies perti-
nent to their safety and efﬁcacy will be described in this review.
RF-based devices for vaginal rejuvenation
RF devices that emit focused electromagnetic waves generating
heat upon meeting tissue impedance have been widely applied for
an array of aesthetic indications in facial and off-face sites, targeting
cellulite, laxity, and noninvasive fat removal (Sadick et al., 2014a,
2014b). Since RF energy is unabsorbed by melanin, the technology
is safe for all skin types and has a proven clinical history in terms of
safety, efﬁcacy, and patient satisfaction. Although transurethral
monopolar RF has been used to treat stress urinary incontinence
withminimal risk of adverse events, nonablative RF has only recently
been explored as a noninvasive strategy to achieve tightening of the
vaginal canal (Dillon and Dmochowski, 2009).
Several devices in the market currently offer RF-based vaginal
rejuvenation. None of these technologies require anesthesia, and on
average, the treatment duration spans 15 to 30 min. Patients report
feeling a sensation of warmth, which is very tolerable, and due to
the lack of downtime, they can resume their normal activities the
same day.
The Protégé Intima from BTL Aesthetics, (Framingham, MA)
exploits focused RF with built-in safety features that allow collagen
remodeling treatments at high energy levels, without temperatures
reaching the skin’s surface or compromising patient comfort.
The Pelleve device from Ellman International (Hicksville, NY),
which emits monopolar RF and is widely used for facial skin rejuve-
nation, has been used off-label for nonsurgical reduction of the labia
majora. The device’s thermal energy denatures the dermal collagen,
inducing remodeling and tissue tightening and subsequent reduction
of redundant skin in the area. Treatments at monthly intervals for
three or four sessions have been recommended to achieve optimal
clinical results (Hamori, 2014).
The ReVive from Viora (Jersey City, NJ) employs bipolar RF energy
that utilizes three distinct RF frequency channels (0.8 MHz, 1.7 MHz,
and 2.45 MHz) and an additional fourth multichannel mode, com-
bining all three RF frequencies to improve labial skin laxity and
texture using the unit’s V-ST handpiece. This proprietary technology
is designed to ensure accurate energy delivery for safe and painlesstreatments, broader dermal effect, and higher energy absorption for
optimal clinical results. The V-ST handpiece emits RF energy ﬂuency
of up to 130 J/cm3 with pulse duration of up to 200 ms and includes
an integral cooling mechanism that cools the electrodes to 6 °C.
A single-center blinded study with 14 healthy female patients,
mean age of 50 years, investigating the safety and efﬁcacy of V-ST
handpiece for labial skin laxity and texture demonstrated moderate
improvement score according to the investigator ratings with 67%
of the patients reporting great satisfactionwith the treatment results.
Patients underwent an average of 5.6 treatments with no anesthesia,
which lasted 30 min, and sessions were at 2- to 3-week intervals.
Treatments were well tolerated by all patients with no adverse
events or side effects recorded (Steven et al., 2014).
The Viveve System from Viveve Medical, (Sunnyvale, CA) uses a
proprietary form of RF-based energy to remodel collagen and restore
the tissue in the vaginal introitus. The system’s efﬁcacy is bolstered by
a strong safety proﬁle and fast patient recovery. Two clinical reports
have been published demonstrating the efﬁcacy of the device for
vaginal laxity following vaginal delivery.
Millheiser et al. (2010) conducted a pilot study in 24 women
(aged 25–44 years) using reverse gradient RF energy (75–90 J/cm2),
delivered through the vaginal mucosa. Post-treatment assessments
were at 10days and1, 3, and 6months. Results from the study showed
that after 1month, post-treatment self-reported vaginal tightness sig-
niﬁcantly improved in 67% of subjects and in 87% at 6 months. Mean
sexual function scores also improved, and no adverse events were
reported. In another prospective single-arm study by Sekiguchi et al.
(2013), 30 premenopausal women (aged 21–52 years) were treated
with a single 30-min ofﬁce treatment using Viveve at 90 J/cm2. Results
included signiﬁcant improvement in sexual function at 6months in all
subjects and decreased in distress related to sexual activity. Subjects
also reported decreased vaginal laxity within the ﬁrst month after
the procedure, and effectiveness was sustained through 12 months.
Another RF-based device, ThermiVa from ThermiAesthetics,
(Southlake, TX) uses an S-shaped handpiece that tightens external
and internal vulvovaginal tissue via a thermistor tip, which also
controls heat delivered to the skin. Monitoring of tissue temperature
is done via a minimally invasive treatment probe.
In a prospective study by Alinsod (2015), 23 subjects (age range
26–58 years, mean 43.6 years; median vaginal births= 2, mean parity
1.7; 5 menopausal, 6 perimenopausal) with mild to moderate
vulvovaginal laxity, sexual dysfunction, and mild to moderate stress
urinary incontinence were treated using the ThermiVa device for ap-
proximately 5 min per zone. The clinical endpoint was achievement
of the target temperature range of 40 °C to 45 °C for approximately 3
to 5 min per zone (or longer, depending on heat tolerance). This was
followed by treatment of the mucosal surface of the vaginal introitus
starting at the hymenal ring and advancing to approximately 4 to
9 cm into the cavity for each zone of the vaginal wall. Total treatment
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of three treatments with the device, at an interval of approximately
4–6 weeks. Assessment occurred at baseline, 10 days after ﬁrst treat-
ment, before second treatment, before third treatment, and 30 days
after the third treatment session. Patients were able to resume all
activity as normal, including sexual intercourse, immediately after
each treatment. All patients experienced a tightening result imme-
diately after the ﬁrst treatment with a signiﬁcant change in the
vaginal laxity score by 3 points on a 7-point scale at the second treat-
ment visit. Signiﬁcant improvement in sexual satisfaction and
decrease in urinary incontinence was also noted. Treatments were
well tolerated, and no adverse effects were reported.
Laser-based devices for vaginal rejuvenation
Minimally ablative fractional laser therapy has gained acceptance as
a safe, precise, and efﬁcientmethod for skin resurfacing and restoration,
especially in the ﬁeld of plastic surgery and dermatology. The basis of
fractional photothermolysis lies in using an array of small laser beams
to create many microscopic areas of thermal necrosis within the skin,
known as microscopic treatment zones. Epidermis and dermis within
the microscopic treatment zones are destroyed inducing a wound-
healing cascade with subsequent new collagen and elastin ﬁber forma-
tion that translates into healthier, ﬁrmer, and tighter skin (Ross et al.,
1996; Sandel and Perkins, 2008). The CO2 (10,600 nm) and the
Er:YAG laser, with its 2,940-nm wavelength that emits laser energy in
the mid-infrared invisible light spectrum are the most widely used la-
sers in the skin rejuvenation ﬁeld and have recently been applied to
the vaginal tissues a for the treatment of symptomatic vulvar and vagi-
nal atrophy (Gambacciani and Levancini, 2015; Gambacciani et al.,
2015a, 2015b; Hutchinson-Colas and Segal, 2015).
Several fractional ablative lasers have been utilized for noninvasive
rejuvenation of the vaginal canal and their safety proﬁle, and efﬁcacy
has been underscored by peer-reviewed clinical studies. Typically,
treatment sessions last 10 to 20 min, and no anesthetic is required.
Most patients report almost no discomfort other than a warming
sensation, but if a patient prefers, a topical anesthetic cream can be
applied prior to treatment. No downtime is required, and regular
activities can be resumed the same day.
MonaLisa Touch, which was developed in Europe by DEKA
(Florence, Italy) and is now distributed in the United States by
Cynosure, Inc. (Westford, MA), is a CO2 laser designed to stimulate
and promote the regeneration of collagen ﬁbers and to restore hydra-
tion and elasticity within the vaginal mucosa. The device is targeted
for the treatment of atrophic vaginitis, vaginal laxity, mild urinary
incontinence, or other sexual problems related to postpartum. It has
also been utilized as an ancillary instrument in female genital surgery
(labioplasty, vaginal reshaping, and clitoral unhooding), ensuring that
surgery is effective and safe while also reducing postoperative discom-
fort. The MonaLisa fractional CO2 laser uses patented DOT Therapy to
apply laser energy to the vaginal walls in a noncontinuous mode in
small 200-micron dots, thus directly affecting only a small percentage
of vaginal tissue. Different types of probes (360°, single-mirror, dis-
posable, and vulvar applicator) accompany the device to adapt to
the speciﬁc clinical and/or anatomic needs of individual patients.
Salvatore et al. analyzed ex vivo vaginal specimens from postmeno-
pausal women and observed tissue remodeling without damage to
surrounding tissue, after the application of fractional CO2 laser tech-
nology (Salvatore et al., 2015a, 2015b). A subsequent study assessing
the efﬁcacy of microabalative fractional CO2 laser in treating sexually
active menopausal patients who had dyspareunia related to
vulvovaginal atrophy showed signiﬁcant improvement reported at
12-week follow-up (Salvatore et al., 2014).
In an independent study by Zerbinati et al. (2015) on biopsies from
vaginal mucosa samples extracted from 50 postmenopausal,nonestrogenized women treated with the MonaLisa, restoration of the
vaginal thick squamous stratiﬁed epithelium with a signiﬁcant storage
of glycogen in the epithelial cells was observed together with ﬁbroblast
activation and neosynthesis of extracellular matrix. The laser settings
used in this study were energy ﬂuence above 100 mJ per pulse, with a
pulse duration of 1,000 μs, and a single spot size of 200 μm.
Salvatore et al. conducted a prospective study in 77 postmeno-
pausal women (mean age 60 years) treated for vulvovaginal atrophy
with MonaLisa Touch to investigate the effect of treatment on sexual
satisfaction. Sexual function and quality of life were evaluated with
the Female Sexual Function Index and the Short Form12, respectively,
both at baseline and at 12-week follow-up. A 10-mm visual analog
scale was used to measure the overall satisfaction with sexual life
and the intensity of vulvovaginal symptoms (vaginal burning, vaginal
itching, vaginal dryness, dyspareunia, and dysuria) before and after
the study period. Results demonstrated a signiﬁcant improvement in
the total score and the scores in each speciﬁc domain of the Female
Sexual Function Index at 12-week follow-up compared to baseline
as well as signiﬁcant overall satisfaction with sexual life. Seventeen
out of 20 women, sexually inactive because of the severity of their
condition, regained a normal sexual life at the 12-week follow-up
(Salvatore et al., 2015a).
Gaspar et al. evaluated the effects of vaginal fractional CO2 laser
combinedwith local application of platelet-rich plasma (PRP) and pel-
vic ﬂoor exercise for improving vaginal dryness, dyspareunia, and
local irritation. The study group underwent PRP, CO2 laser, and pelvic
exercise, whereas only PRP and pelvic exercise were applied to the
control group. Results showed histological evidence of an increase in
the ﬁbrillar component of the extracellular matrix and vaginal epithe-
lial thickness and a decrease of discomfort during sex inmost patients
in the study group compared with the control group (Gaspar et al.,
2011). Perino et al. (2015) also conﬁrmed safety, efﬁcacy, and patient
satisfaction following vaginal laser therapy for treating symptoms of
vulvovaginal atrophy.
Similar to theMonaLisa, the FemiLift laser fromAlma Lasers (Buffalo
Grove, IL) is another device speciﬁcally designed to offer minimally
invasive CO2 laser-based treatment that induces collagen deposition
via concentrated thermal heating of the inner vaginal tissue layer.
The second type of ablative laser being utilized for vaginal rejuve-
nation is the Er:YAG laser with a 2,940-nmwavelength, which emits
laser energy in the mid-infrared invisible light spectrum. This laser
has 10 to 15 times the afﬁnity for water absorption compared with
the carbon dioxide wavelength (10,600 nm). In a comparative study
using the ablative fractional lasers for vaginal tightening, in which
one group received ablative CO2 laser therapy while the other group
underwent treatment with a nonablative Er:YAG laser, improvement
in vaginal tightening was observed in both groups; however, more
complications were recorded in CO2-treated patients (Adrian, 2012).
IntimaLaser by Fotona (based in the United States and Europe) is a
2,940-nm, nonablative Er:YAG laser with proprietary “smooth-mode”
technology that delivers energy to the vaginal mucosa tissue in a fast
sequence of low-ﬂuence laser pulses inside an overall super-long
pulse of several hundred milliseconds, resulting in a nonablative
heating to a depth of 100 microns that tightens the vaginal canal via
neocollagenesis and remodeling. Another Er:YAG laser recently
released in the market is the Action II Petit Lady from Lutronic, Inc.
(Fremont, CA), which enables practitioners to effectively treat a
wide range of vulvovaginal symptoms and conditions, including
vulvovaginal atrophy and urinary incontinence. The Action II Petit
Lady features a dual mode that automatically combines multiple
micropulses with long-pulsemodes. This new treatment approach en-
ables a deeper secondary thermal effect and the controlled heating of
the target mucous membrane of the vaginal wall.
Several clinical studies have utilized the Er:YAG for both improve-
ment of vulvovaginal atrophy and stress urinary incontinence. In a
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syndrome ofmenopause received three treatments at 30-day intervals
with Er:YAG laser (spot size 7 mm, 1.6 Hz, 6.0 J/cm2), and the results
were compared with the effects of a standard treatment of hormonal
vaginal gel therapy in a group of 25 postmenopausal women. Results
demonstrated that compared to the vaginal gel, the Er:YAG treatment
led to signiﬁcant decrease in both vaginal dryness and dyspareunia as
well as signiﬁcant improvement of urinary incontinence. The effects
were rapid and long lasting, up to the 24thweek of the observation pe-
riod, and treatments were well tolerated with less than 3% of patients
discontinuing treatment due to adverse events (Gambacciani et al.,
2015a, 2015b).
Ogrinc et al. (2015) evaluated the effects of Er:YAG laser in 175
women (mean age 49 years) suffering from stress urinary inconti-
nence. The subjects were treated two times at a 2-month interval
with the IntimaLase laser set in “smooth mode” (ﬂuence 10.0 J/cm2;
four pulses per packet, packet pulse duration 250 ms; spot size
7 mm; repetition rate 1.6 Hz), and follow-ups were performed at 2,
6, and 12 months after the treatment. Results of the study showed
that 77% of the subjects experienced a signiﬁcant improvement after
treatment, and only 34% of women exhibited mild urinary inconti-
nence at the 1-year follow-up. No major adverse effects were noted,
and treatments were well tolerated.
Finally, an international multicenter observational study is current-
ly underway to evaluate the efﬁcacy and safety of Er:YAG laser for the
treatment of genitourinary syndrome and stress urinary incontinence
called the Vaginal Erbium Laser Academy Study (VELAS). This study
will evaluate the effects of three laser applications in mid-infrared
1,500 postmenopausal women. Subjective and objective symptoms
will be evaluated at baseline with follow-up visits after 4 weeks from
the last laser application, and subsequently every 3 months for
1 year. Findings from the VELAS have the potential to affect clinical
care practice and health decisions for millions of women worldwide
and substantiate the use of laser-based devices for the amelioration
of genitourinary conditions (Gambacciani et al., 2015b).Conclusion
Newprevention, treatment, andmanagement strategies are contin-
uously explored to alleviate medical and aesthetic concerns in women
regarding their genital area. The emergence of energy-based devices
enableswomen and their physicians to have another treatment option
in their armamentarium to consider, while weighing the associated
risks and beneﬁts. Although there is a lack of a robust, qualitative
body of data on the therapeutic advantages of these technologies for
vaginal rejuvenation, the research ﬁeld is very active with large multi-
center studies currently being conducted to facilitate the acquisition of
knowledge and best practices (Digesu, 2015; Singh et al., 2015). Laser
and RF technologies are widely and successfully used for treatments
in dermatology and aesthetic medicine, stimulating the remodeling
tissue properties and inducing the production of new collagen and
elastic ﬁbers. Thus, their application in the vaginal canal for feminine
rejuvenation simply represents an expansionof therapeutic indications
and hallmarks their versatility and the reactivity of biologic tissues to
the beneﬁcial effects of their mechanism of action. In the hands of
well-trained physicians, energy-based devices are likely to beneﬁt
millions ofwomenby aiding them in reclaiming, relishing, and reveling
in their femininity at full capacity.References
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